Virion Therapeutics Reports Broad and Sustained Anti-HBV Immunity Following a Single VRON-0200 Dose in the Majority of Chronically HBV-Infected Patients From...
Virion Therapeutics reported that a single VRON-0200 dose generated broad, sustained anti-HBV T-cell immunity in most chronically infected patients in its Phase 1b study presented at CROI 2026.
Why it mattersPhase 1b VRON-0200 anti-HBV data suggests reprioritizing R&D budgets toward T-cell immunotherapy platforms.